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ABSTRACT
Objective To examine the presence and extent of small
study effects in clinical osteoarthritis research.
DesignMeta-epidemiological study.
Data sources 13 meta-analyses including 153
randomised trials (41605 patients) that compared
therapeutic interventions with placebo or non-
intervention control in patients with osteoarthritis of the
hip or knee and used patients’ reported pain as an
outcome.
MethodsWe compared estimated benefits of treatment
between large trials (at least 100 patients per arm) and
small trials, explored funnel plots supplemented with
lines of predicted effects and contours of significance,
and used three approaches to estimate treatment effects:
meta-analyses including all trials irrespective of sample
size, meta-analyses restricted to large trials, and
treatment effects predicted for large trials.
Results On average, treatment effects were more
beneficial in small than in large trials (difference in effect
sizes −0.21, 95% confidence interval −0.34 to −0.08,
P=0.001). Depending on criteria used, six to eight funnel
plots indicated small study effects. In six of 13 meta-
analyses, the overall pooled estimate suggested a
clinically relevant, significant benefit of treatment,
whereas analyses restricted to large trials and predicted
effects in large trials yielded smaller non-significant
estimates.
Conclusions Small study effects can often distort results
of meta-analyses. The influence of small trials on
estimated treatment effects should be routinely
assessed.
INTRODUCTION
The methodological quality and unbiased dissemina-
tion of clinical trials is crucial for the validity of sys-
tematic reviews and meta-analyses. It has often been
suggested that small trials tend to report larger treat-
ment benefits than larger trials.1 2 Such small study
effects can result from a combination of lower metho-
dological quality of small trials and publication and
other reporting biases2-8 but could also reflect clinical
heterogeneity if small trials were more careful in
selecting patients and implementing the experimental
intervention.9 The funnel plot is a scatter plot of
treatment effects against standard error as a measure
of statistical precision.9 10 Imprecision of estimated
treatment effects will increase as the sample size of
component trials decreases. Thus, in the absence of
small study effects, results from small trials with large
standard errors will scatter widely at the bottom of a
funnel plot while the spread narrows with increasing
sample size and the plot will resemble a symmetrical
inverted funnel. Conversely, if small study effects are
present, funnel plots will be asymmetrical.9 The plot
can be enhanced by lines of the predicted treatment
effect from meta-regression with the standard error as
explanatory variable11 12 and contours that divide the
plot into areas of significance and non-significance.13 14
A recent study of trials of anti-depressants15 found that
these approaches increased the understanding of the
interplay of several biases associatedwith small sample
size, including publication bias, selective reporting of
outcomes, and inadequate methods and analysis.14
Small study effects are not uncommon in osteoar-
thritis research; several recent meta-analyses found
pronounced asymmetry of funnel plots.16-18 We pre-
viously studied the influence of methodological char-
acteristics on estimated effects in a set of clinical
osteoarthritis trials that used pain outcomes reported
by patients and found that deficiencies in concealment
of random allocation, blinding of patients, and ana-
lyses can distort the results in these trials.19 20 Different
components of inadequate trial methods often concur.
A trial with adequate allocation concealment, for
example, is more likely to report analyses according
to the intention to treat principle.19 20 Meta-epidemio-
logical studies found that smaller trials are less likely to
use adequate random sequence generation, adequate
allocation concealment, and double blinding78 19 and
that different methodological components are asso-
ciated with exaggerated benefits of treatment.7 8 19-23
We explored the presence and extent of small study
effects in meta-analyses of osteoarthritis trials using
three different approaches: analyses stratified accord-
ing to sample size, inspection of funnel plots, and
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prediction of treatment effects based on the standard
error used as a measure of statistical precision of trials.
We then determined whether sensitivity analyses
based on a restriction of meta-analyses to large appro-
priately powered trials or based on a prediction of
treatment effects in large trials influenced conclusions
of meta-analyses.
METHODS
Selection of meta-analyses and component trials
We included meta-analyses of randomised or quasi-
randomised controlled trials in patients with osteoar-
thritis of the knee or hip.Meta-analyses were eligible if
they included a pain related outcome reported by
patients for any intervention compared with placebo,
sham, or no control intervention. Two reviewers inde-
pendently evaluated reports of meta-analyses for elig-
ibility. Details of the search strategy and selection
process are described elsewhere.20 Reports of all com-
ponent trials from included meta-analyses were
obtained. No language restrictions were applied.
Data extraction and quality assessment
Two reviewers used a standardised form to indepen-
dently extract data from individual trials regarding
design, interventions, year of publication, trial size,
sample size calculation, exclusions, and results.20 The
primary outcome was pain. If different pain related
outcomeswere reported,we extracted one pain related
outcome per study according to a pre-specified
hierarchy.16 19 24 Concealment of treatment allocation
was considered as adequate if investigators responsible
for selection of patients were unable to suspect before
allocation which treatment was next—for example,
central randomisation or sequentially numbered,
sealed, opaque envelopes. Blinding of patients was
considered adequate if experimental and control inter-
ventions were described as indistinguishable or if a
double dummy technique was used. Handling of
incomplete outcome data was considered adequate if
all randomised patients were included in the analysis
(intention to treat principle). We used a cut-off of an
average of 100 randomised patients per treatment
arm to distinguish between small and large trials, irre-
spective of the number of patients subsequently
excluded from the analysis. A two arm trial with 110
patients in one arm and 95 patients in the second arm,
for example, was classified as large. A sample size of
2×100 patients will yield more than 80% power to
detect a small to moderate effect size of −0.40 at a two
sided α=0.05, which corresponds to a difference of 1
cm on a 10 cm visual analogue scale between experi-
mental and control intervention in a two arm trial.
Data synthesis
We expressed treatment effects as effect sizes by divid-
ing the difference inmeanvalues at the endof follow-up
by the pooled standard deviation (SD). Negative effect
sizes indicate a beneficial effect of the experimental
intervention. If some required data were unavailable,
we used approximations as previously described.16
Within each meta-analysis, we estimated effect sizes of
large (≥100patients per trial arm) and small trials (<100
patients per trial arm) separately, using inverse var-
iance random effectsmeta-analysis, calculated theDer-
Simonian and Laird estimate of the variance τ2 as a
measure of heterogeneity between trials,25 26 and
derived differences between pooled estimates of large
and small trials. We then combined these differences
acrossmeta-analyses using an inverse variance random
effects model, which fully allowed for heterogeneity
between meta-analyses.2627 Meta-analyses that
included exclusively small or exclusively large trials
did not contribute to the analysis. Negative differences
in effect sizes indicate that small trials show more ben-
eficial treatment effects than large trials. The variability
between meta-analyses was quantified with the hetero-
geneity variance τ2. To account for the correlation
between sample size and methodological quality, we
used stratification by these components in analogy to
Mantel-Haenszel procedures28 and derived differences
between small and large trials adjusted for concealment
of allocation, blinding of patients, and intention to treat
analysis. We performed analyses of associations
between sample size and estimated treatment benefits,
stratified according to the following pre-specified
characteristics20: heterogeneity between trials in the
overall meta-analysis (low (τ2<0.06) v high (τ2≥0.06)),
treatment benefit in the overall meta-analysis (small
(effect sizes >−0.5) v large (effect sizes ≤−0.5)),24 29 and
type of intervention assessed in themeta-analysis (drug
v other interventions, conventional v complementary
medicine). These stratified analyses were accompanied
by interaction tests based on z scores, which are defined
as the difference in effect sizes between strata divided
by the standard error (SE) of the difference.
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Fig 1 | Difference in effect sizes between 95 small trials with fewer than 100 patients per arm
and 58 large trials. Negative differences indicate that small trials show more beneficial
treatment effects. P values are for interaction between sample size and effect sizes.
NSAIDs=non-steroidal anti-inflammatory drugs
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We drew funnel plots, plotting effect sizes of indivi-
dual trials on the x axis against their SEs on the y axis.
Under the assumption that effect sizes of individual
studies are normally distributed, significance of any
point of the funnel plot can be derived directly from
effect sizes and corresponding SE with Wald tests.13 30
As previously described, we used this to enhance fun-
nel plots by contours dividing the plot into areas of
significance with a two sided P≤0.05 and areas of
non-significance with a P>0.05.13 30 If trials seem to be
missing in areas of non-significance, this adds to the
notion of the presence of bias.13 14 We added lines to
the funnel plots, which represented the predicted treat-
ment effect derived from univariable random effects
meta-regression models using the SE as explanatory
variable.11 12 Then, we assessed funnel plot asymmetry
with regression tests, a weighted linear regression of
the effect sizes on their SEs, using the inverse of the
variance of effect sizes as weights.2 9 Asymmetry coeffi-
cients, defined as the difference in effect size per unit
increase in SE,10 11 were combined with inverse var-
iance random effects models, crude and adjusted for
adequate concealment of allocation, blinding of
patients, and intention to treat analysis.Negative asym-
metry coefficients indicate that estimated treatment
benefits increase with increasing SEs.
We compared three different approaches to estimate
treatment effects: pooled effect sizes from overall ran-
dom effects meta-analyses, pooled effect sizes from ran-
dom effects meta-analyses restricted to large trials only,
and predicted effect sizes from random effects meta-
regression models using the SE as explanatory variable
for trials with a SE of 0.1.1214 A SE of 0.1 is found in a
large two arm trial with 200 randomised patients per
group, which will have more than 95% power to detect
aneffect size of about−0.40SDunits,which corresponds
to the median minimal clinically important difference
found in recent trials in patients with osteoarthritis.31-34
Results were considered concordant if point estimates
differed by less than 0.10 SD units35 and if the status of
significance at a two sided α=0.05 remained unchanged,
as indicated by the presence or absence of an overlap of
the 95% confidence interval with the null effect. Finally,
we compared pooled effect sizes, heterogeneity between
trials, precision defined as the inverse of the SE, and P
values for pooled effect sizes between random effects
meta-analyses including all trials and meta-analyses
including large trials only, using Wilcoxon’s rank tests
for paired observations. All P values are two sided. All
data analysis was performed in Stata version 10 (Stata-
Corp, College Station, TX).
RESULTS
The study sample and its origin are described
elsewhere.19 20 Twenty one meta-analyses described
in 17 reports were eligible. Of these, 13 meta-
analyses16 36-46 (153 trials with 41 605 patients) included
both small and large trials and contributed to the cur-
rent analyses. The median number of trials included
per meta-analysis was 12 (range 3-24) and the median
number of patients was 1849 (347-13 659). The pooled
effect sizes ranged from −0.07 to −1.11 and the hetero-
geneity between trials from a τ2 of 0.00 to 0.47. Eight
meta-analyses assessed drug interventions, and five
assessed non-drug interventions. Four assessed inter-
ventions in complementary medicine, and nine
assessed interventions in conventional medicine.
Table 1 describes the characteristics of the 153 com-
ponent trials; 58 (38%) trials included at least 100
patients per arm and 95 (62%) trials were smaller. The
number of allocated patients ranged from 201 to 2957
in large trials, and from 8 to 362 in small trials. Large
trialswere publishedmore recently (P=0.001) andwere
more likely to report adequate concealment of alloca-
tion (P=0.01) and calculation of sample size (P<0.001).
The average difference in effect sizes between large
and small trials across the 13 included meta-analyses
was −0.21 (95% confidence interval −0.34 to −0.08,
P=0.001), with more beneficial effects found in small
trials (fig 1). At the level of individual meta-analyses,
tests for interaction between treatment benefits and
trial size were positive in four meta-analyses
(31%).16373945 The variability across meta-analyses was
small to moderate, with a τ2 estimate of 0.03 (P=0.005).
Table 2 shows the average difference in effect sizes
between large and small trials, both crude and after
adjustment for the methodological quality of trials. Dif-
ferences in effect sizes between small and large trials
were robust after adjustment for blinding of patients
(−0.21, −0.33 to −0.09, P=0.001), slightly attenuated
after adjustment for concealment of allocation (−0.16,
Table 1 | Comparison of characteristics between small and large trials in meta-analyses in
osteoarthritis research. Figures are numbers (percentages)
No of allocated patients
P value*<100 per arm (n=95) ≥100 per arm (n=58)
Concealment of allocation:
Adequate 19 (20) 22 (38)
0.010
Inadequate/unclear 76 (80) 36 (62)
Blinding of patients:
Adequate 41 (43) 30 (52)
0.25
Inadequate/unclear 54 (57) 28 (48)
Intention to treat analysis:
Yes 16 (17) 16 (28)
0.23
No/unclear 79 (83) 42 (72)
Sample size calculation:
Reported 37 (39) 38 (66)
<0.001
Not reported 58 (61) 20 (34)
Year of publication:
1980-98 45 (47) 11 (19)
0.001
1999-2007 50 (53) 47 (81)
Drug intervention†:
Yes 70 (74) 43 (74)
0.97
No 25 (26) 15 (26)
Complementary medicine‡:
Yes 30 (32) 11 (19)
0.09
No 65 (68) 47 (81)
*Derived from logistic regression models adjusted for clustering of trials within meta-analyses.
†Includes chondroitin, diacerein, glucosamine, NSAIDs, opioids, paracetamol, and viscosupplementation.
‡Includes acupuncture, balneotherapy, chondroitin, and glucosamine.
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−0.27 to −0.06, P=0.002), but nearly halved after adjust-
ment for intention to treat analysis (−0.12, −0.21 to
−0.02, P=0.016). The variability across meta-analyses
was similar between crude and adjusted analyses.
Table 3 presents results from analyses stratified
according to themagnitude of treatment effects, the het-
erogeneity between trials found in overall meta-ana-
lyses, and the type of experimental intervention.
Differences in effect sizes between large and small trials
were most pronounced in meta-analyses with large
treatment benefits, meta-analyses with a high degree of
heterogeneity between trials, andmeta-analyses of com-
plementary interventions (P for interaction all <0.001).
Figure 2 shows funnel plots of all 13 meta-analyses
including prediction lines from meta-regression mod-
els with the SE as an explanatory variable and 5% con-
tour areas to display areas of significance and non-
significance. For six funnel plots, the scatter of effect
estimates and the prediction line indicated asymmetry
(A, D, G, H, L, M). 16 37 39 42 44 45 For two other funnel
plots, the prediction linesmainly suggested asymmetry
(C, E), 40 46 whereas the remaining five funnel plots
seemed symmetrical and prediction lines nearly
upright (B, F, I, J, K). 36 38 41 43 44 The regression test was
significant at P≤0.05 in four meta-analyses (D, G, H,
M)1637 39 42 and showed a statistical trend in another
two (P≤0.10,A, L). 44 45 In five funnel plots, the contours
to distinguish between areas of significance and non-
significance at P=0.05 suggested missing trials in areas
of non-significance (A, C, D, H, L). 16 42 44-46 The
weighted average of asymmetry coefficients across all
meta-analyses was −1.79 (−2.81 to −0.78). This indi-
cates that, on average, the estimated treatment benefit
increases by 1.79 SD units for each unit increase in the
SE. It was much the same after adjustment for conceal-
ment of allocation (−1.86, −2.98 to −0.74), slightly
more pronounced after adjustment for blinding
(−2.22, −3.28 to −1.17), but slightly less pronounced
Table 2 | Estimates of small study effects in meta-analyses of osteoarthritis trials
Difference in effect sizes Variability†
(P value)Difference* (95% CI) P value
Overall, crude −0.21 (−0.34 to −0.08) 0.001 0.03 (0.005)
Adjusted for methodological component:
Concealment of allocation −0.16 (−0.27 to −0.06) 0.002 0.02 (0.06)
Blinding of patients −0.21 (−0.33 to −0.09) 0.001 0.03 (0.010)
Intention to treat analysis −0.12 (−0.21 to −0.02) 0.016 0.01 (0.18)
*Difference in effect size between 95 small and 58 large trials.
†Estimate of between meta-analyses heterogeneity variance (τ2).
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Fig 2 | Funnel plots of 13 included meta-analyses including prediction lines from univariable meta-regression models with SE as explanatory variable (dashed
red) and 5% contour areas to display areas of significance (blue) and non-significance (pale blue). Lines for predicted effects should be interpreted
independently of contours delineated by shaded areas. Extent of deviation of lines for predicted effects from vertical line should be considered, irrespective of
relation of lines to contours. P values derived from regression tests for asymmetry. NSAIDs=non-steroidal anti-inflammatory drugs
RESEARCH
page 4 of 8 BMJ | ONLINE FIRST | bmj.com
after adjustment for intention to treat analysis (−1.41,
−2.27 to −0.54). Confidence intervals of adjusted and
the unadjusted estimates overlapped widely.
Figure 3 presents a graphical summary of results of
individualmeta-analyses of all trials (blue circle),meta-
analyses restricted to large trials (open circle), and pre-
dicted effect sizes for trials with a SE of 0.1 (green
square). Results of all three analytical approaches
were concordant in seven meta-analyses (fig 3, B, E,
F, H, I, J, K). 36 38 41-44 In the six remaining, both
approaches, the restricted analysis, and the predicted
effect were discordant to the overall analysis (A, C, D,
G, L, M). 16 37 39 44-46 In three of these, significance at the
conventional level of 0.05 was lost when the analysis
was restricted to large trials and when predicting the
effect (D, G, M); in the other three, significance was
lost when predicting the effect but not when the analy-
sis was restricted (A, C, L). 44-46 The median estimated
treatment benefit decreased from −0.39 (range −1.11-
−0.06) in meta-analyses of all trials to −0.23 (−0.59-
−0.04) in meta-analyses restricted to large trials
(P=0.005) and themedian heterogeneity between trials
decreased from a τ2 of 0.20 (0.00-0.69) to a τ2 of 0.04
(0.00-0.31, P=0.030). P values of pooled effect sizes
increased from a median of <0.001 (<0.001-0.13) to
0.007 (<0.001-0.61, P=0.016) in restricted meta-ana-
lyses, whereas precisions of pooled effect sizes were
much the same (median 13 (2-24) v 14 (7-21), P=0.70).
DISCUSSION
In thismeta-epidemiological study of 13meta-analyses
of 153 osteoarthritis trials, we found larger estimated
benefits of treatment in small trials with fewer than 100
patients per trial arm compared with larger trials. The
average difference between small and large trials was
about half the magnitude of a typical treatment effect
found for interventions in osteoarthritis.24 Small study
effects, however, weremore prominent in five of the 13
meta-analyses. These showed a large extent of
statistical heterogeneity, larger pooled estimates of
treatment benefit than would typically be expected
from an effective intervention in osteoarthritis, and
mainly covered complementary medical inter-
ventions. Taking into account contours used to distin-
guish between areas of significance and non-
significance and lines of treatment effects predicted
for different standard errors, we found eight funnel
plots suggestive of small study effects. Finally, we
used three different approaches to estimate treatment
effects of the 13 interventions included in this study:
pooling all trials irrespective of sample size, restricting
the analysis to large trials of at least 100 patients per
trial arm, and predicting treatment effects for large
trials using the corresponding standard error as inde-
pendent variable. Estimates from these three
approaches were discordant in six meta-analyses,
with the overall pooled estimate suggesting a clinically
relevant, significant benefit of treatment, which was
not found in the other two approaches aimed at esti-
mating the effect in large trials only.
Strengths and limitations of the study
Large trials tend to be of higher quality than small trials
and the observed association between sample size and
treatment effect could be confounded by methodologi-
cal quality.78 47 When accounting for blinding of
patients, we found the association between sample size
and treatment effect to be completely robust. Adjust-
ment for concealment of allocation resulted in a slight
attenuation, whereas adjustment for the presence or
absence of an intention to treat analysis nearly halved
the association between sample size and treatment
effect. This suggests that problems with exclusions
from the analysis after randomisation might contribute
to the observed small study effects, which is in line with
the findings of a recent study of trials of anti
depressants.15 In addition to publication and reporting
biases, switching from an intention to treat to a per
Table 3 | Analyses stratified according to characteristics of meta-analyses of osteoarthritis trials
Comparison No of meta-analyses No of trials
Difference in effect sizes
(95% CI) Variability* (P value) P for interaction†
Overall 13 153 −0.21 (−0.34 to −0.08) 0.03 (0.005) —
Treatment benefit in overall meta-analysis:
Small benefit 10 115 −0.13 (−0.22 to −0.03) 0.01 (0.17)
<0.001
Large benefit 3 38 −0.72 (−1.02 to −0.43) 0.00 (0.90)
Heterogeneity between trials in overall meta-analysis:
Low heterogeneity 8 87 −0.08 (−0.16 to −0.00) 0.00 (0.66)
<0.001
High heterogeneity 5 66 −0.55 (−0.73 to −0.36) 0.00 (0.46)
Drug intervention‡:
Yes 8 113 −0.23 (−0.39 to −0.08) 0.03 (0.021)
0.67
No 5 40 −0.17 (−0.40 to 0.06) 0.03 (0.041)
Complementary medicine§:
Yes 4 41 −0.70 (−0.95 to −0.45) 0.00 (0.96)
<0.001
No 9 112 −0.10 (−0.18 to −0.03) 0.00 (0.43)
*Estimate of between meta-analyses heterogeneity variance (τ2).
†Derived from interaction tests based on z scores.
‡Includes chondroitin, diacerein, glucosamine, NSAIDs, opioids, paracetamol, and viscosupplementation.
§Includes acupuncture, balneotherapy, chondroitin, and glucosamine.
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protocol analysis seemed to contribute to discrepancies
between published and unpublished results.14 The
assessment of components of methodological quality
will depend strongly on reporting quality48 and might
be affected by misclassification, whereas sample size or
standard error might be extracted more easily. Sample
size or statistical precision might therefore be the best
single proxy for the cumulative effect of the different
sources of bias in randomised trials in osteoarthritis
and probably also in other fields: selection, perfor-
mance, detection, and attrition bias49; selective report-
ing of outcomes34; and publication bias.6 50
Themost important limitation of our study is that we
cannot exclude alternative explanations of small study
effects other than bias: smaller trials might have been
more careful in implementing the intervention or in
including patients who are particularly likely to benefit
from the intervention, which could result in larger
treatment effects and true clinical heterogeneity.2 9 51
Selection of patients and implementation of inter-
ventions might be particularly important for complex
interventions. For example, in a meta-analysis of inpa-
tient geriatric consultations, some differences in
observed effects between small and large trials could
be explained by more careful implementation of the
intervention by experienced consultants.9 52 The low
quality of reporting, however, makes it difficult to
examine this issue systematically, and we are unaware
of any methodological study to have dealt with this.
Interestingly, for four out of fivemeta-analyses of com-
plex interventions in our study (aquatic exercise, bal-
neotherapy, exercise, and self management), we found
little evidence for asymmetrical funnel plots, and only
for acupuncture, as a complex complementary inter-
vention, was there evidence of asymmetry. Investiga-
tors should be careful to report the selection of patients
and the implementation of interventions in sufficient
detail, particularly in trials of complex interventions,
to allow a more systematic appraisal of this issue in
the future. In addition, the selection of component
trials was based on the literature searches and selection
criteria of published meta-analyses. Some of the
searches in these meta-analyses could have been too
superficial and some of the selection criteria too nar-
row to include a large proportion of unpublished trials.
Themeta-analyses included in our study, however, are
probably representative, and we believe therefore that
our results are generalisable. Another limitation is that
our analysis was based on published information only
and depends on the quality of reporting, which is often
unsatisfactory.49
Comparison with other studies
To our knowledge, this is the first meta-epidemiologi-
cal study to systematically assess small study effects in a
series of meta-analyses with continuous clinical out-
comes. In an analysis of trials with binary outcomes,
Kjaergard et al7 8 found more beneficial treatment
effects in small trials with inadequate methodology
compared with large trials. In an analysis of homoeo-
pathy trials Shang et al found that smaller trials and
those of lower quality show more beneficial treatment
effects than larger and higher quality trials.11Moreno et
al recently assessed the performance of contour
enhanced funnel plots and a regression based adjust-
mentmethod to detect and adjust for small study effects
in placebo controlled antidepressant trials previously
submitted to the US Food and Drug Administration
(FDA) and matching journal publications.14 Applica-
tion of the regression based adjustment method to the
journal data produced a similar pooled effect to that
observed by a meta-analysis of the complete unbiased
FDA data. In contrast to our study, Moreno et al
regressed treatment effects against their variance,
which performed well in a simulation study but has
been shown to give similar results to using the standard
Effect size
-1.0 -0.5 0 0.5 1.0 -1.0 -0.5 0 0.5 1.0 -1.0 -0.5 0 0.5 1.0
Effect size Effect size
-1.0 -0.5 0 0.5 1.0 -1.0 -0.5 0 0.5 1.0
Effect size Effect size
Restricted to large trials
Predicted at SE=0.1
Overall meta-analyses
A) Acupuncture45 B) Aquatic exercise43 C) Balneotherapy46 D) Chondroitin16 E) Diacerein40
F) Exercise36 G) Glucosamine39 H) Opioids42 I) Oral NSAIDs44 J) Paracetamol41
K) Self management38 L) Topical NSAIDs44 M) Viscosupplementation37
Fig 3 | Results of individual random effects meta-analyses of all trials (blue circle), results of random effects meta-analyses restricted to large trials with at least
100 patients per arm (open circle), and effect sizes for trials with SE of 0.1 predicted from random effects meta-regression models (green square). NSAIDs=non-
steroidal anti-inflammatory drugs
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error as an explanatory variable.12 In funnel plots, how-
ever, treatment effects will typically be plotted against
their standard error, and significance tests will be gen-
erally based on z or t values, which again are directly
derived from standard errors. Therefore, we deem it
preferable to regress treatment effects against the stan-
dard error rather than the variance. A second discre-
pancy is that Moreno et al predicted effects for
infinitely large trials of a variance of zero.12 By defini-
tion, such a trial would be overpowered to detect a
minimally clinically relevant difference between
groups and we deem it preferable to predict treatment
effects for large trials with adequate power to detect
small, albeit relevant effects. The chosen SE of 0.1 will
typically be found in a large two arm trial with a con-
tinuous primary outcome including 200 patients per
group. Such a trial will yield more than 95% power to
detect an effect size of −0.40 SD units and still more
than 80% power to detect an effect size of about −0.30
SD units. Trials considerably larger than that will prob-
ably not be needed for continuous primary outcomes.
The meta-regression model used to predict effects
incorporates residual heterogeneity unexplained by
regressing treatment effect against standard error. In
case of large unexplained heterogeneity, it will appro-
priately indicate uncertainty in the predicted estimate
as reflected by a wide 95% prediction interval, even
though an analysis restricted to large trials might yield
precise estimates. This was observed in five meta-ana-
lyses in our study373944-46 andwas taken as an indication
of residual uncertainty necessitating additional
explorations of sources of heterogeneity or additional
appropriately designed large scale trials. For continu-
ous outcomes, definitions of large trials and methods
used for assessing funnel plot asymmetrymight be gen-
erally suitable, as reported here. Trials with an average
of 100 patients per trial armwill yield about 80%power
to detect a small to moderate effect size of −0.40 SD
units, which corresponds to the median minimal clini-
cally important difference found in recent studies in
patients with osteoarthritis.32-34 For binary outcomes,
the definition of large trials will depend on event rates
in the control group and a definition of what constitutes
a moderate but clinically relevant effect. In addition,
the regression test for funnel plot asymmetry originally
reported9 might be associated with an inappropriately
high rate of false positives if odds ratios or risk ratios are
used. Therefore, a modification of the test should be
considered, as reported by Harbord et al.51 Non-para-
metric tests will result in lower power than the regres-
sion tests discussed here andmight be less appropriate.
Similarly, funnel plots and analyses stratified according
to sample size might be inconclusive if the range of
sample sizes or standard errors of included trials is
restricted. For example, the meta-analysis of diacerein
trials in our study included only moderately sized to
large trials, but no small trials, and firm conclusions
about the presence or absence of small study effects
might not be possible.
Conclusions and implications
An inspection of funnel plots and stratified analyses
according to sample size accompanied by appropriate
interaction tests should be considered as routine pro-
cedures in any meta-analysis, possibly accompanied
by a regression test for funnel plot asymmetry and pre-
diction of effects in large trials with meta-regression.47
In the presence of asymmetry in funnel plots, systema-
tic reviews should also report meta-analyses restricted
to large trials or effects predicted for large trials. Read-
ers and clinicians should be careful in interpreting
results of small trials of low methodological quality
and meta-analyses including mainly such trials.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Small study effects refer to a tendency of small trials to report larger benefits of treatment
than larger trials
Such effects can result from a combination of lowermethodological quality of small trials and
publication and other reporting biases or from true clinical heterogeneity
Contour enhanced funnel plots and regression tests can be used to identify small study
effects in meta-analyses
WHAT THIS STUDY ADDS
Small study effects often affect results of meta-analyses in osteoarthritis research
Sample size or statistical precision might be the best single proxy for the cumulative effect of
the different sources of bias in randomised osteoarthritis trials and probably also in other
specialties
In the presence of small study effects, restriction of analyses to large trials or predictions of
treatment benefits observed in large trials might provide more valid estimates than overall
analyses of trials, irrespective of sample size
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